Targets › PVRIG
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Sep 2027.
Cell surface receptor for NECTIN2. May act as a coinhibitory receptor that suppresses T-cell receptor-mediated signals. (UniProt, Q6DKI7)
Open in Phaseline: the race on PVRIG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hefei TG ImmunoPharma Co., Ltd. | NM1F Injection Anti-PVRIG monoclonal antibody | PVRIG | Phase 1 | Ovarian Cancer | Sep 2027 |
| D3 Bio (Wuxi) | D3L-002 Bispecific antibody targeting TIGIT and PVRIG | TIGIT, PVRIG | Phase 1 | Advanced Solid Tumor | Nov 2027 |
Advanced Solid Tumor (1) Ovarian Cancer (1)
small molecule (1), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.